JP2024508969A - 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ - Google Patents

新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ Download PDF

Info

Publication number
JP2024508969A
JP2024508969A JP2023554812A JP2023554812A JP2024508969A JP 2024508969 A JP2024508969 A JP 2024508969A JP 2023554812 A JP2023554812 A JP 2023554812A JP 2023554812 A JP2023554812 A JP 2023554812A JP 2024508969 A JP2024508969 A JP 2024508969A
Authority
JP
Japan
Prior art keywords
ankyrin repeat
binding
protein
human
repeat domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023554812A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022190010A5 (https=
JP2024508969A5 (https=
Inventor
ニーナ レシュケ
クリスティアン ライヒェン
ベルント シュレーレス
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2024508969A publication Critical patent/JP2024508969A/ja
Publication of JPWO2022190010A5 publication Critical patent/JPWO2022190010A5/ja
Publication of JP2024508969A5 publication Critical patent/JP2024508969A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Electroluminescent Light Sources (AREA)
JP2023554812A 2021-03-09 2022-03-09 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ Pending JP2024508969A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163158539P 2021-03-09 2021-03-09
US63/158,539 2021-03-09
US202163172818P 2021-04-09 2021-04-09
US63/172,818 2021-04-09
US202163265179P 2021-12-09 2021-12-09
US63/265,179 2021-12-09
PCT/IB2022/052120 WO2022190010A1 (en) 2021-03-09 2022-03-09 Novel darpin based cd33 engagers

Publications (3)

Publication Number Publication Date
JP2024508969A true JP2024508969A (ja) 2024-02-28
JPWO2022190010A5 JPWO2022190010A5 (https=) 2025-03-18
JP2024508969A5 JP2024508969A5 (https=) 2025-03-18

Family

ID=80933410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554812A Pending JP2024508969A (ja) 2021-03-09 2022-03-09 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ

Country Status (6)

Country Link
US (1) US20240317852A1 (https=)
EP (1) EP4304730A1 (https=)
JP (1) JP2024508969A (https=)
AU (1) AU2022231913A1 (https=)
CA (1) CA3211248A1 (https=)
WO (1) WO2022190010A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
IL305677A (en) 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025163082A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513370A (ja) * 2009-12-09 2013-04-22 フリードリヒ−アレクサンダー−ウニベルジテート・エアランゲン−ニュルンベルク 急性骨髄性白血病に対する三重特異性治療剤
JP2014501509A (ja) * 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513370A (ja) * 2009-12-09 2013-04-22 フリードリヒ−アレクサンダー−ウニベルジテート・エアランゲン−ニュルンベルク 急性骨髄性白血病に対する三重特異性治療剤
JP2014501509A (ja) * 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MABS, vol. 2017, VOL. 9, NO. 8, JPN6025051026, 31 October 2017 (2017-10-31), pages 1262 - 1269, ISSN: 0005752560 *

Also Published As

Publication number Publication date
US20240317852A1 (en) 2024-09-26
WO2022190010A1 (en) 2022-09-15
EP4304730A1 (en) 2024-01-17
CA3211248A1 (en) 2022-09-15
AU2022231913A1 (en) 2023-09-28
AU2022231913A9 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
TWI825086B (zh) Her3抗原結合分子
JP2024508969A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
KR102290592B1 (ko) Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질
JP2024509241A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ１２３エンゲージャ
JP7611173B2 (ja) 組換えｆａｐ結合タンパク質及びそれらの使用
US20250074994A1 (en) Novel darpin based cd70 engagers
CN107636014A (zh) 抗癌融合多肽
TW201936638A (zh) 雙特異性異質二聚體雙功能抗體及彼等之用途
JP2023554379A (ja) 組換えｃｄ３結合タンパク質及びそれらの使用
CN104379741B (zh) 抗人cd69抗体及其用于医疗目的的用途
KR20230155464A (ko) 신규한 DARPin-기반 다중특이성 T-세포 인게이저
WO2024251628A1 (en) Recombinant cd16a binding proteins and their use
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN117242100A (zh) 基于DARPin的新型CD70接合物
CN117177996A (zh) 基于DARPin的新型CD123接合物
CN121263440A (zh) 重组cd2结合蛋白及其用途
WO2025146490A1 (en) Recombinant cd117 binding proteins and their use
CN116802213A (zh) 重组cd3结合蛋白及其用途
JP2025532665A (ja) 腫瘍への抵抗における抗体およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316